NASH-TAG 2021
March 11-13, 2021
To help you get as much value from NASH-TAG 2021 as possible, we have identified several presentations and articles we find most interesting. Our daily podcasts will summarize these and discuss what they suggest for the future of NASH/NAFLD therapies.
Advanced Notification
S3-E26 – What Are We Learning About Clinical Trial Best Practices For NITs?
Quentin Anstee joins the Surfers (including Stephen Harrison) to share lessons about the proper use of non-invasive tests in the clinical trial process and to explore implications for best practices and future research or research.
S3-E25.6 – Emerging Concepts In NASH: NAFLD Patient Screening, NASH Management
Surfing the NASH Tsunami shares Dr. Marcelo Kugelmas’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD patient screening and diagnostics along with NASH patient management. After this, he answers questions from Roger Green, who then interviews Dr. Naim Alkhouri on disease prevalence and strategies for bringing patient to be tested.
S3-E25.5 – Emerging Concepts in NASH: Fatty Liver Pathophysiology, Epidemiology, Co-Morbidities
Surfing the NASH Tsunami shares Dr. Mazen Noureddin’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD pathophysiology and NASH epidemiology. After this, he answers questions from Roger Green.
S3-E25.4 – NASH Drug Development in 2022: Will Quality of Life Data Help NASH Drugs Over the Finish Line?
Jörn Schattenberg, Louise Campbell and Roger Green wrap up the discussion of NASH drug development in 2022 by citing their reasons for optimism, ranging from what researchers have proven already about safety and efficacy to the likelihood that combination therapy will eventually become the core therapeutic strategy and the emerging importance of quality of life measures.
S3-E25.3 – Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green all discuss the role that combination NASH drugs and greater population diversity in clinical trials will strengthen NASH drug development.
S3-E25.2 – NASH Drug Development In 2022: A Wealth of Data and a Promising NASH Pipeline
The discussion of drugs in development continues, with specific focus on the treasure trove of data Intercept is producing for OCA and why combination therapy will probably be critical element in the long-term treatment strategy for NASH.